Wyeth’s farm team
Executive Summary
Wyeth's "most interesting" developmental project "from a scientific point of view" is the anti-GDF8 antibody MYO-029, in Phase I as a potential treatment for type II diabetes and for wasting diseases, CEO Robert Essner told the J.P. Morgan H&Q conference Jan. 7 in San Francisco. The antibody targets myostatin, which is believed to decrease muscle mass and increase fat and glucose levels in the blood. Essner showed a picture of the Belgian Blue Bull, a species that naturally lacks GDF8; it is "an animal that is massive, is muscled, is low fat, but otherwise lives a very healthy normal lifecycle." If the compound advances in development, it could give Wyeth a new barnyard symbol to supplant the pregnant mares that provide the raw material for the company's flagship conjugated estrogens line...
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.